A Review On Itepekimab: An Investigational Drug

Faisal Shaikh*, Dr. G.J. Khan, Rehan Deshmukh, Aman Shaikh, M Sohil M Shabbir

JIIU’s Ali Allana College of Pharmacy Akkalkuwa, Dist-Nandurbar -425415, Maharashtra, India

Correspondence: sk1999faisal@gmail.com; Tel.: (+91 9146621487)

­­­

INTRODUCTION

Severe type 2 asthma can be effectively treated with monoclonal antibodies that target IgE, interleukin-4 and -13, and interleukin-5; however, additional targets are required. A novel monoclonal antibody called itepekimab targets the upstream alarmin interleukin-33. It is uncertain if itepekimab, either alone or in combination with dupilumab, is safe and effective for asthmatic individuals (1). Genetic evidence links IL-33 to an increased risk of developing asthma. A monoclonal antibody called itepekimab, which targets IL-33, has shown promise in treating chronic obstructive pulmonary disease (COPD) and asthma. Our first goal in this work was to investigate the possibility that COPD was also linked to genetic variations in the IL-33 pathway. We carried out this phase 2a because respiratory conditions including asthma and COPD are strongly linked to genes in the IL-33 pathway.

We carried out this phase 2a study to evaluate the safety and effectiveness of itepekimab in patients with moderate-to-severe COPD who were receiving a stable regimen of triple-inhaled or double-inhaled background maintenance treatment since these genes are linked to respiratory disorders such asthma and COPD (2)(3)(4).

"A response which arises in vascularized tissue upon exposure to infections and damaging stimuli, which recruits host defence cells to the site of exposure to eliminate the harmful agents" is the traditional definition of inflammation. When inflammation is operating properly, it serves as an instantaneous reaction to pathogens present at the lesion site. The innate immune response, which is the immune system's initial line of defense, includes inflammation. Inflammation is often an acute occurrence that aids in wound healing. Leukocytes go to the area of inflammation, eliminate the pathogens, and aid in tissue healing.

Leukocytes go to the inflammatory location, eliminate the pathogens, and aid in tissue healing. On the other hand, persistent inflammation may result from dysregulation (5)(6). Chronic inflammation is a harmful process that involves abnormal, ongoing inflammation that eventually results in tissue change and destruction. Numerous disease units have chronic inflammation as their pathophysiological foundation, with the respiratory system being affected by some of the most common and serious illnesses. One of the main causes of death and serious illness in the globe is chronic inflammation of the lungs. According to estimates, there were 262 million active cases of asthma in 2019, which resulted in 455 thousand fatalities globally.

 Only ischemic heart disease and malignant neoplasms cause more fatalities globally than chronic obstructive pulmonary disease (CO Inhaled corticosteroids and beta-adrenergic agonists are common treatments for the symptoms of chronic inflammatory lung disease, but prolonged use of these medications is associated with increasingly severe side effects. To ensure ongoing patient compliance necessary to effectively manage these conditions, new pharmacological targets related to the pathophysiology of inflammation must be considered and understood. A variety of cell signalling pathways, related to a network of receptors and ligands, have been linked to inflammation; targeted inhibition of select elements within these pathways may be a superior approach to anti-inflammatory drug design (8)(9).

PD), which ranks third in terms of mortality. An estimated 174 million individuals globally were thought to have COPD in 2015, which resulted in around 3.2 million deaths (7).

Common treatments for the symptoms of chronic inflammatory lung disease include beta-adrenergic agonists and inhaled corticosteroids, which are both extensively used and effective. However, long-term, consistent use of these medications is associated with progressively worse negative effects. New pharmaceutical targets linked to the biology of inflammation must be taken into account and comprehended in order to guarantee the ongoing patient compliance needed to appropriately manage these disorders. Inflammation has been connected to a variety of cell signalling pathways that are connected to a network of receptors and ligands. Targeted inhibition of certain components within these pathways could be a better strategy to build anti-inflammatory medications.(8)(9) This review describes a selection of biologic inhibitors which are currently undergoing research and clinical trials as potential treatments for chronic inflammatory lung diseases. Peptide inhibitor-based treatments have already been proposed for a range of diseases, including infectious diseases, cancers, and even Alzheimer disease,(11)(12), while monoclonal antibodies have already been implemented as therapeutics for a range of conditions. Inhibiting specific pathways to manage chronic inflammation has many advantages over classical approaches to treatment because the drugs target the underlying pathophysiology of a given disease directly rather than managing its symptoms.

Asthama

In the lower and upper respiratory tract, asthma is the most prevalent chronic inflammatory illness. It is characterized by bronchial hyperresponsiveness to various stimuli, which results in reversible expiratory flow restriction and bronchoconstriction. With a great deal of variation in both phenotypes (clinical manifestations) and endotypes (underlying pathophysiological mechanisms), asthma is a diverse illness. Shortness of breath, coughing, chest tightness, and wheezy breathing are typical symptoms. Mostly occurring during asthma flare-ups, symptoms might vary in intensity and frequency. Two main endotypes of bronchial asthma may be identified by the presence of inflammatory responses triggered by type 2 T-helper cells (Th2).

The two endotypes of asthma that are traditionally recognized are non-type 2 (non-eosinophilic) and type 2 (eosinophilic). The ability of type 2 innate lymphoid cells (ILC2s) to generate Th2 cytokines allowed for a more accurate division of asthma endotypes into three categories: T2-high, T2-low, and non-T2.(13). Asthma etiology is now understood to be caused by the production of inflammatory mediators, particularly several interleukins, by epithelial cells in response to bronchial hyperresponsiveness to ordinarily innocuous antigens like pollens or mites. The mediators set off a series of immune activation events that include mast cells, Th2s, eosinophils, dendritic cells Repeated exposure to allergens can cause chronic airway inflammation and airway remodeling, which can lead to loss of pulmonary function. In asthma, airway remodeling includes subepithelial fibrosis, extracellular matrix deposition, goblet cell proliferation, smooth muscle and mucosal gland hypertrophy, and epithelial damage (14). A variety of novel biologic agents and small molecule inhibitors are currently undergoing preclinical testing and clinical trials, many of which target only factors responsible for specific endotypes, such as monoclonal antibodies targeting type 2 cytokines. (15) Dupilumab is a fully human anti-IL4-Rα mAb that has been used to treat all conditions related to type 2 inflammation. The use of the mAb has been associated with a significant decrease in the rate of asthma exacerbations and a reduction in the rate of oral corticosteroid usage, especially in patients with elevated FENO and blood eosinophil levels.

COPD

Smoking of tobacco-based products is known to be the leading cause of chronic obstructive pulmonary disease (COPD), a chronic, progressive inflammatory lung disease that is expected to become the third leading cause of death worldwide. It is characterized by small airway impediment and destruction of lung parenchyma, resulting in aberrant lung function and unremitting airflow limitation(17)(18). The exact pathogenesis of COPD is not yet fully understood, but mechanisms such as oxidative stress, protease-antiprotease imbalance, and inflammation triggered by a range of pollutants and tobacco smo The primary cause of COPD is recognized to be tobacco-based product smoking.(19)(20) Smoking causes inflammatory cells to infiltrate the lung epithelium and causes persistent inflammation in the lung tissues. Immune cell-released factors irritate functioning lung tissue over time. Collagen is deposited as a result of repetitive tissue repair at inflammatory sites, which eventually thickens the bronchial walls and narrows the tiny airways. As the illness are thought to be key risk factors. develops, the lungs' capacity to generate extracellular matrix (ECM) is diminished, and the protease-antiprotease equilibrium is disrupted, leading to the development of emphysema and the deterioration of lung parenchyma.(21).(22) Although eosinophilic inflammation is seen in 20–40% of patients, neutrophilic inflammation is the predominant type of inflammation associated with COPD. In rarer patient subgroups, a mix of neutrophilic and eosinophilic inflammation may also be present, maybe in different proportions.(23) Other immune cells may also contribute to the inflammation of COPD, including dendritic cells, B and T cells, epithelial cells, and macrophages. Proteases, ROS, and cytokines are among the complex mediators produced by these cell types in COPD.(24) The underlying processes of pathophysiology and the relative contributions of neutrophil-associated (T1) and eosinophil-associated (T2) inflammation are expected to influence the variation in patient-specific illness subtypes.(25).

The concept of treatments that might alter chronic lung inflammation in COPD has received a lot of interest because corticosteroid therapy is ineffective for the majority of COPD airway diseases.26 Consequently, the main goals of COPD medication research are to create substances that can either directly or indirectly prevent the recruitment and activation of inflammatory cells mediated by COPD by focusing on inflammatory mediators and preventing their interaction with inflammatory cells themselves. On the other hand, individuals with COPD are more susceptible to severe and ongoing lung infections. Such medications may worsen this elevated risk by compromising the immunological responses of the patient.(27). Anti-inflammatory medications like corticosteroids and bronchodilators like β2-adrenergic agonists or antimuscarinics are the two main pharmacological strategies for managing COPD. The initial efforts to create biologics for COPD therapy have concentrated on addressing the mechanisms of T1 inflammation because the majority of COPD patients include neutrophilic inflammation. These initial attempts, however, were not entirely successful, and negative side effects were frequent.(28). Clinical studies have not shown any benefits in patient health, and attempts at safe and effective mAb-mediated CXCR2 inhibition(29) and TNF-α inhibition(30) have also failed due to a high rate of side effects. In order to treat COPD-related eosinophilia, more efforts at COPD biologics have focused on this condition.(31).

Phosphodiesterase inhibitors, chemokine receptor inhibitors, p38 MAPK inhibitors, PI3K inhibitors, and anti-IL17A mAbs are among the pharmacological classes that have been successfully used to prevent immune cell recruitment and activation in vitro. A number of anti-IL17A mAbs are being researched as possible treatments for COPD. However, certain anti-IL17A mAbs, such CNTO 6785, have been demonstrated to make bacterial infections associated with COPD worse in patients, while other anti-IL17A mAbs, including COVA322, NI-1401, secukinumab, or brodalumab, have not yet been studied on COPD patients.(32)(33) Anti-IL5 and anti-IL4 mon It has been demonstrated that mepolizumab and benralizumab, which were first authorized for the treatment of asthma, lower the incidence of exacerbations in patients with COPD who have eosinophilia. As previously mentioned, T2 inflammation is known to be influenced by TSLP, IL-4, and IL-13. Because of this, randomized clinical trials are being used to evaluate dupilumab, an anti-IL4Rα monoclonal antibody that is approved for the treatment of asthma, and tezepelumab, an anti-TSLP monoclonal antibody that is also approved for the treatment of asthma, in patients with COPD who have eosinophilia.

oclonal antibodies are also being studied for COPD since a particular proportion of COPD patients show T2 inflammation

PATENT 

Received (Europe EP3088517A1 - Human anti-il-33for  progressive inflammatory lung disease has registered by the Sanofi.(34)   

DOSE

Itepekimab is administered subcutaneously (75 or 150 mg each week for 4 weeks) and intravenously (0.3, 1.3, or 10 mg/kg infusion)

CLINICAL TRIAL

1. Clinical Trial on Asthma

In individuals with moderate-to-severe asthma, itepekimab-induced interleukin-33 inhibition improved lung function and reduced the occurrence of events suggesting a loss of asthma control compared to placebo. Sanofi and Regeneron Pharmaceuticals provided funding for this study; its ClinicalTrials.gov code is NCT03387852.(2)

METHOD

We randomly assigned adults with moderate-to-severe asthma who were receiving inhaled glucocorticoids and long-acting beta-agonists (LABAs) in a 1:1:1:1 ratio to receive subcutaneous itepekimab (300 mg), itepekimab plus dupilumab (both at 300 mg; combination therapy), dupilumab (300 mg), or placebo every two weeks for a total of 12 weeks. Following randomization, LABA was stopped at week four, and weeks six through nine saw a tapering down of inhaled glucocorticoids. An event suggesting a loss of asthma control was the main outcome, and it was measured in both the combination and itepekimab groups in comparison to the placebo group. Safety, quality of life, type 2 biomarkers, lung function, and asthma management were secondary and additional end goa

2. Clinical Trial on COPD

 In conclusion, this is the first trial to show that a biological treatment may improve lung function and exacerbation rate in COPD patients who had previously smoked when added to conventional medication. In these cases, itepekimab-induced IL-33 inhibition may be beneficial and well-tolerated. To validate and further understand the potential of this innovative treatment for COPD, two phase 3 clinical trials are underway. ClinicalTrials.gov has registered this trial (NCT03546907).

Genetic studies showed that a decrease in IL33 function was linked to a lower risk of COPD, whereas an increase in risk was linked to IL33 and IL1RL1 variations. In the phase 2 study that followed. Although the population's primary objective was not reached, subgroup analysis revealed that itepekimab improved lung function and decreased the risk of exacerbations in ex-smokers.

with COPD. Two phase 3 clinical trials are being conducted to verify itepekimab's effectiveness and safety profile in COPD patients who had previously smoked.

Methods  

The genetic studies of gain-of-function and loss-of-function variations in the IL-33 pathway, which were previously linked to asthma risk, were first characterized for COPD in this two-part investigation. After that, we conducted a double-blind, phase 2a trial at 83 study sites across 10 countries, comparing itepekimab with a placebo in patients with moderate-to-severe COPD who were still receiving conventional medication. Current or former smokers between the ages of 40 and 75 who had been diagnosed with COPD for at least a year and were receiving a stable regimen of triple-inhaled or double-inhaled background maintenance therapy were randomly assigned (1:1) to receive itepekimab 300 mg or a placebo, which were given as two subcutaneous injections every two weeks for 24–52 weeks.

The phase 2a trial's main outcome was the annualized rate of moderate-to-severe acute exacerbations of COPD during the course of treatment. The primary secondary result was the shift in prebronchodilator FEV1 between baseline and weeks 16–24. Analysis of predefined subgroups, including smoking status, was performed for every outcome. For the modified intention-to-treat population, all individuals who received at least one dose of the assigned therapy underwent efficacy and safety assessments. 35)

CONCLUSION

Biologic drugs are a class of treatment that is anticipated to have a significant increase in both importance and prevalence, as evidenced by the numerous current clinical trials. Biologics provide significant benefits over small molecule medications presently used to treat chronic lung inflammation. Patients who have low tolerance to corticosteroid therapy can benefit greatly from the use of certain monoclonal antibodies, such as mepolizumab and omalizumab, which are currently being used to treat asthma. The danger of side effects is greatly decreased by the extremely rare administration of other biologics, such as depemokimab, even once every six months.

Small molecule medications will undoubtedly continue to be the primary anti-inflammatory therapy for the foreseeable future, even with the notable advancements in the creation of biologic medicines for chronic inflammatory lung disorders. Biological therapies in general continue to confront a number of obstacles, including relatively significant immunogenicity concerns and expensive development and production costs. The gradual creation of a varied and complementary pharmacological library comprising both small molecule and biologic therapies would be the most ideal course for anti-inflammatory therapy in the future.

REFERENCES

1.           Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa G Della, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol [Internet]. 2001;108(2):184–90. Available from: https://www.sciencedirect.com/science/article/pii/S0091674901659451

2.           Rabe KF, Celli BR, Wechsler ME, Abdulai RM, Luo X, Boomsma MM, et al. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a  genetic association study and randomised, double-blind, phase 2a trial. Lancet Respir Med. 2021 Nov;9(11):1288–98. 

3.           Miyaoka C, Watanabe M, Nakamoto K, Yoshida Y, Hirata A, Aso J, et al. Association of IL-33 in modeling type-2 airway inflammation and pulmonary  emphysema in mice. Immunity, Inflamm Dis. 2024 Apr;12(4):e1252. 

4.           Jo YS, Rhee CK, Yoon HK, Park CK, Lim JU, An TJ, et al. Evaluation of asthma-chronic obstructive pulmonary disease overlap using a mouse  model of pulmonary disease. J Inflamm (Lond). 2022 Dec;19(1):25. 

5.           Plichta J, Kuna P, Panek M. Biologic drugs in the treatment of chronic inflammatory pulmonary diseases:  recent developments and future perspectives. Front Immunol. 2023;14:1207641. 

6.           Medzhitov R. Origin and physiological roles of inflammation. Nature [Internet]. 2008;454(7203):428–35. Available from: https://doi.org/10.1038/nature07201

7.           GBD. Global burden of 369 diseases and injuries in 204 countries and territories, 19902019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet (London, England). 2020 Oct;396(10258):1204–22. 

8.           Upadhyay R, Sanchez-Hidalgo A, Wilusz CJ, Lenaerts AJ, Arab J, Yeh J, et al. Host Directed Therapy for Chronic Tuberculosis via Intrapulmonary Delivery of  Aerosolized Peptide Inhibitors Targeting the IL-10-STAT3 Pathway. Sci Rep. 2018 Nov;8(1):16610. 

9.           Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683–765. 

10.       Schütz D, Ruiz-Blanco YB, Münch J, Kirchhoff F, Sanchez-Garcia E, Müller JA. Peptide and peptide-based inhibitors of SARS-CoV-2 entry. Adv Drug Deliv Rev. 2020 Dec;167:47–65. 

11.       Liu M, Li C, Pazgier M, Li C, Mao Y, Lv Y, et al. D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy  of malignant neoplasms. Proc Natl Acad Sci U S A. 2010 Aug;107(32):14321–6. 

12.       Kumar J, Sim V. D-amino acid-based peptide inhibitors as early or preventative therapy in  Alzheimer disease. Prion. 2014;8(1):119–24. 

13.       Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. 2015 Jan;16(1):45–56. 

14.       Chiu C-J, Huang M-T. Asthma in the Precision Medicine Era: Biologics and Probiotics. Int J Mol Sci. 2021 Apr;22(9). 

15.       Matucci A, Vivarelli E, Nencini F, Maggi E, Vultaggio A. Strategies Targeting Type 2 Inflammation: From Monoclonal Antibodies to  JAK-Inhibitors. Biomedicines. 2021 Oct;9(10). 

16.       Kyriakopoulos C, Gogali A, Bartziokas K, Kostikas K. Identification and treatment of T2low asthma in the era of biologics. ERJ open Res. 2021 Apr;7(2). 

17.       Postma DS, Bush A, van den Berge M. Risk factors and early origins of chronic obstructive pulmonary disease. Lancet (London, England). 2015 Mar;385(9971):899–909. 

18.       Barnes PJ. Small airway fibrosis in COPD. Int J Biochem Cell Biol. 2019 Nov;116:105598. 

19.       Zhu J, Kovacs L, Han W, Liu G, Huo Y, Lucas R, et al. Reactive Oxygen SpeciesDependent Calpain Activation Contributes to Airway and  Pulmonary Vascular Remodeling in Chronic Obstructive Pulmonary Disease. Antioxid Redox Signal. 2019 Oct;31(12):804–18. 

20.       Zeng Q, Zeng J. Inhibition of miR-494-3p alleviates oxidative stress-induced cell senescence and  inflammation in the primary epithelial cells of COPD patients. Int Immunopharmacol. 2021 Mar;92:107044. 

21.       Navratilova Z, Kolek V, Petrek M. Matrix Metalloproteinases and Their Inhibitors in Chronic Obstructive Pulmonary  Disease. Arch Immunol Ther Exp (Warsz). 2016 Jun;64(3):177–93. 

22.       Vestbo J, Hurd SS, Rodriguez-Roisin R. The 2011 revision of the global strategy for the diagnosis, management and  prevention of COPD (GOLD)--why and what? Clin Respir J. 2012 Oct;6(4):208–14. 

23.       David B, Bafadhel M, Koenderman L, De Soyza A. Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable  trait. Thorax. 2021 Feb;76(2):188–95. 

24.       King PT. Inflammation in chronic obstructive pulmonary disease and its role in  cardiovascular disease and lung cancer. Clin Transl Med. 2015 Dec;4(1):68. 

25.       Brightling C, Greening N. Airway inflammation in COPD: progress to precision medicine. Eur Respir J. 2019 Aug;54(2). 

26.       Barnes PJ. Identifying Molecular Targets for New Drug Development for Chronic Obstructive  Pulmonary Disease: What Does the Future Hold? Semin Respir Crit Care Med. 2015 Aug;36(4):508–22. 

27.       Cazzola M, Matera MG. Is it time to look beyond bronchodilators and corticosteroids in treating COPD? Vol. 3, Future Drug Discovery. Future Science; 2021. p. FDD61.